Biogen To Offer Continuity of Care Plan for U.S. Patients Currently Treated with ADUHELM® (aducanumab-avwa)
April 28, 2022 - … of Care Plan for U.S. Patients Currently Treated with ADUHELM (R) (aducanumab-avwa) … Biogen To Offer Continuity of Care Plan for U.S. Patients Currently Treated with ADUHELM(R) (aducanumab-avwa) Biogen To Offer Continuity of Care Plan for U.S. Patients Currently Treated with ADUHELM(R) (aducanumab-avwa) April 28, 2022 Company …
Biogen Statement Regarding Updated ADUHELM® (aducanumab-avwa) Prescribing Information in US
April 29, 2022 - … Biogen Statement Regarding Updated ADUHELM (R) (aducanumab-avwa) Prescribing Information in US … Biogen Statement Regarding Updated ADUHELM(R) (aducanumab-avwa) Prescribing Information in US Biogen Statement Regarding Updated ADUHELM(R) (aducanumab-avwa) Prescribing Information in US …
Update on Regulatory Submission for Aducanumab in the European Union
April 22, 2022 - … options to people living with Alzheimer's disease. ADUHELM (aducanumab-avwa) was approved by the U.S. Food and … details on the indication are provided below. About ADUHELM(R) (aducanumab-avwa) injection 100 mg/mL solution for intravenous use In the U.S., ADUHELM (aducanumab-avwa) injection 100 mg/mL solution for …
Biogen’s Statement on the Final National Coverage Determination for Amyloid-Beta Targeting Therapies for the Treatment of Alzheimer’s Disease
April 7, 2022 - … effectively denies all Medicare beneficiaries access to ADUHELM (R) (aducanumab-avwa), the first and only … continuity of care for Medicare beneficiaries already on ADUHELM. Biogen is carefully considering its options and will … evaluates the business impact of this decision. About ADUHELM (R) (aducanumab-avwa) injection 100 mg/mL for …
Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years
March 16, 2022 - … Long-Term Phase 3 Data Show ADUHELM (R) Continues to Reduce Underlying Pathologies of … for More Than Two Years … Long-Term Phase 3 Data Show ADUHELM(R) Continues to Reduce Underlying Pathologies of … for More Than Two Years Long-Term Phase 3 Data Show ADUHELM(R) Continues to Reduce Underlying Pathologies of …
Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease
March 16, 2022 - … Biogen Announces Peer-Reviewed Publication of ADUHELM (R) Phase 3 EMERGE and ENGAGE Data in The Journal of … Disease … Biogen Announces Peer-Reviewed Publication of ADUHELM(R) Phase 3 EMERGE and ENGAGE Data in The Journal of … Disease Biogen Announces Peer-Reviewed Publication of ADUHELM(R) Phase 3 EMERGE and ENGAGE Data in The Journal of …
Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
March 30, 2022 - … Biogen Submits Final Protocol for ADUHELM (R) (aducanumab-avwa) Phase 4 ENVISION Trial to FDA … Biogen Submits Final Protocol for ADUHELM(R) (aducanumab-avwa) Phase 4 ENVISION Trial to FDA Biogen Submits Final Protocol for ADUHELM(R) (aducanumab-avwa) Phase 4 ENVISION Trial to FDA …
Biogen to Present New Research at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022)
March 11, 2022 - … new Alzheimer's disease research, as well as data for ADUHELM (R) (aducanumab-avwa) injection 100 mg/mL for … on March 16, will include an examination of the ability of ADUHELM to reduce amyloid beta plaque and plasma p-tau181, … endpoints during the long-term extension phase of the ADUHELM clinical program. An oral presentation on March 18, …
Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
March 14, 2022 - … which is commercialized in the United States as ADUHELM (R) (aducanumab-avwa). Effective as of January 1, … Eisai will receive a tiered royalty based on net sales of ADUHELM rather than sharing global profits and losses. The … Biogen's existing final decision-making rights on ADUHELM have converted to sole decision making and …
Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®
January 27, 2022 - … Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM (R) … Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM(R) Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM(R) January 27, 2022 Investor Relations General …